Clinical Trials Sponsored by Merk Sharp & Dohme España S.A.

Total 3976 results

Merck Sharp & Dohme LLC

Completed

A Study Investigating the Influence of Hepatic Insufficiency on the Pharmacokinetics of Vaniprevir (MK-7009-005)

Hepatitis C
Merck Sharp & Dohme LLC

Completed

A Study of Safety and Efficacy of Vaniprevir Administered With Pegylated-Interferon and Ribavirin in Japanese Participants With Chronic Hepatitis C Infection (7009-016)

Hepatitis C
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of Vaniprevir (MK-7009) With Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) in Treatment-Experienced Hepatitis C Virus (HCV) Participants (MK-7009-009)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Terminated

A Pharmacokinetic Analysis of Posaconazole in Lung Transplant Recipients (MK-5592-105) (PAPAL)

Fungal Infection
Merck Sharp & Dohme LLC

Completed

A Study to Assess Pharmacokinetics (PK) of Preladenant in Participants With Chronic Renal Impairment (CRI) (P06512)

Parkinson Disease
Merck Sharp & Dohme LLC

Completed

A 6-Month Efficacy and Safety Study of Org 50081 in Adult Patients With Chronic Primary Insomnia (21106/P05701/MK-8265-002)

Mental Disorders | Dyssomnias | Sleep Initiation and Maintenance Disorders | Sleep Disorders | Sleep Disorder, Intrinsic
Merck Sharp & Dohme LLC

Completed

Study of MK-1029 in Participants With Persistent Asthma That Cannot Be Controlled With Montelukast (MK-1029-015)

Asthma
Merck Sharp & Dohme LLC

Completed

A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8150 (MK-8150-002)

Hypertension | Isolated Systolic Hypertension
Merck Sharp & Dohme LLC

Completed

A Study to Assess Pharmacokinetics of Preladenant in Participants With Chronic Hepatic Impairment (P06513)

Chronic Hepatic Impairment
Merck Sharp & Dohme LLC

Completed

Pharmacokinetics of Suvorexant in Participants With Hepatic Insufficiency (MK-4305-017)

Hepatic Insufficiency | Insomnia
Merck Sharp & Dohme LLC

Completed

Safety and Tolerability of MK-5478 in Participants With Hypertension (5478-001)

Hypertension
Merck Sharp & Dohme LLC

Completed

Trial to Assess the Safety of Vorapaxar in Japanese Subjects With Cerebral Infarction (P05005; MK-5348-017)

Cerebral Infarction
Merck Sharp & Dohme LLC

Completed

A Long Term Safety Study of Suvorexant in Participants With Primary Insomnia (MK-4305-009 AM3)

Insomnia
Merck Sharp & Dohme LLC

Terminated

A Study of MK-7145 in Participants With Renal Insufficiency (Part I) and Heart Failure With Renal Insufficiency (Part II) (MK-7145-011)

Heart Failure | Renal Impairment
Merck Sharp & Dohme LLC

Terminated

A Dose-Ranging Study of MK-1029 in Adults With Persistent Asthma (MK-1029-012)

Asthma
Merck Sharp & Dohme LLC

Terminated

Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063)

Hepatitis C, Chronic | Hepacivirus
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Terminated

Pharmacokinetics of Boceprevir in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P07614)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Terminated

A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004)

Type II Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Pharmacokinetic Study of MK-3102 in Participants With Impaired Hepatic Function (MK-3102-031)

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC

Completed

Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)

Type 2 Diabetes
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of MK-8666 in Participants With Type 2 Diabetes Mellitus (MK-8666-003)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Evaluation of Omarigliptin (MK-3102) in Obese Participants and in Participants With Type 2 Diabetes (MK-3102-004)

Type 2 Diabetes (T2D)
Merck Sharp & Dohme LLC

Completed

Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Dose-Range Finding Study in Participants With Type 2 Diabetes (MK-3102-006)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study of the Safety and Efficacy of Omarigliptin (MK-3102) in ≥18 and <45 Year-Old Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK-3102-028)

Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Efficacy and Safety of Boceprevir Added to Standard of Care Therapy in Previously Treated Participants With Chronic Hepatitis C Genotype 1 and Cirrhosis (MK-3034-105)

Hepatitis C
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1293 Compared With a Basal Insulin in Participants With Type 1 Diabetes (MK-1293-005)

Type 1 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study of the Safety and Efficacy of MK-1293 Compared to Lantus™ in Participants With Type 1 Diabetes Mellitus (T1DM) (MK-1293-003)

Type 1 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)

Chemotherapy-Induced Nausea and Vomiting (CINV)
Merck Sharp & Dohme LLC

Completed

Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024)

Mixed Hyperlipidemia
Merck Sharp & Dohme LLC

Terminated

A Study of Odanacatib When Administered to Adolescents and Young Adults Treated With Glucocorticoids (MK-0822-066)

Osteoporosis
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Efficacy of Odanacatib (MK-0822) in Postmenopausal Women Previously Treated With a Bisphosphonate (MK-0822-042)

Osteoporosis
Merck Sharp & Dohme LLC

Terminated

A Study of the Safety and Efficacy of Pegylated Inferferon Alfa-2b (PEG-Intron™) Versus Pegylated Interferon Alfa-2a (PEGASYS™) in Participants With Chronic Hepatitis B (P08450)

Hepatitis B, Chronic
Merck Sharp & Dohme LLC

Terminated

A Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children (P03579)

Fungal Infections
Merck Sharp & Dohme LLC

Terminated

Study of Safety and Pharmacokinetics of MK-8242 in Participants With Advanced Solid Tumors (P07650)

Solid Tumors
Merck Sharp & Dohme LLC

Terminated

A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Pharmacokinetic Study to Evaluate the Effect of MAALOX on Raltegravir (MK-0518) in Human Immunodeficiency Virus (HIV)-Infected Participants (MK-0518-295)

HIV Infections
Merck Sharp & Dohme LLC

Completed

An Investigational Study of Gardasil™ (qHPV Vaccine) in Reducing the Incidence of Anogenital Warts in Young Men (V501-020)

Condylomata Acuminata
Merck Sharp & Dohme LLC

Completed

A Phase II Study of Pegylated Interferon Alfa-2b for the Adjuvant Treatment of Melanoma Subjects in Russia (MK-4031-400)

Melanoma
Merck Sharp & Dohme LLC

Terminated

A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720)

Osteosarcoma | Sarcoma, Ewing's | Peripheral Neuroectodermal Tumor
Merck Sharp & Dohme LLC

Completed

Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Terminated

A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118)

Dyslipidemia | Primary Hypercholesterolemia
Merck Sharp & Dohme LLC

Completed

Effects of Glimepiride on Recovery From Hypoglycemia in Participants With Type 2 Diabetes Mellitus (MK-0000-253)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Terminated

A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)

Neoplasms Malignant
Merck Sharp & Dohme LLC

Completed

Phase I Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Participants With Colorectal Cancer (MK-0646-016)

Colorectal Cancer
Merck Sharp & Dohme LLC

Completed

A Study of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study Evaluating Dalotuzumab (MK-0646) in Combination With Erlotinib for Participants With Non-Small Cell Lung Cancer (MK-0646-007)

Carcinoma, Non-small-cell Lung
Merck Sharp & Dohme LLC

Completed

Dose Escalation Trial of Dalotuzumab (MK-0646) in Advanced Solid Tumors and Multiple Myeloma (MK-0646-001)

Multiple Myeloma | Solid Tumor
Merck Sharp & Dohme LLC

Completed

Study of Dalotuzumab (MK-0646) in Adults With Solid Tumors (MK-0646-009)

Neoplasm

3

Subscribe